• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 425 filed by Locust Walk Acquisition Corp.

    8/23/21 8:57:28 AM ET
    $LWAC
    Get the next $LWAC alert in real time by email
    425 1 d202149d425.htm 425 425

     

     

    United States

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    Form 8-K

     

     

    Current Report

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

    August 23, 2021

    Date of Report (Date of earliest event reported)

     

     

    Locust Walk Acquisition Corp.

    (Exact Name of Registrant as Specified in its Charter)

     

     

     

    Delaware   001-39866   85-3306396

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    200 Clarendon Street, 51st Floor,

    Boston, MA

      02116
    (Address of Principal Executive Offices)   (Zip Code)

    Registrant’s telephone number, including area code: (415) 697-0763

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☒

    Written communications pursuant to Rule 425 under the Securities Act

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading Symbol(s)

     

    Name of each exchange on

    which registered

    Class A Common Stock, par value $0.0001 per share   LWAC   Nasdaq Capital Market
    Warrants to purchase one share of Class A Common Stock   LWACW   Nasdaq Capital Market
    Units, each consisting of one share of Class A Common Stock and one- third of one Warrant   LWACU   Nasdaq Capital Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    Item 8.01 Other Events.

    On August 8, 2021, Locust Walk Acquisition Corp. (“LWAC” or the “Company”) filed with the Securities and Exchange Commission (the “SEC”) a registration statement on Form S-4, which includes a document that will serve as a prospectus and proxy statement, referred to as a proxy statement/prospectus, in connection with a proposed business combination (the “Business Combination”) with eFFECTOR Therapeutics, Inc. (”eFFECTOR”). Among the matters to be voted upon at the special meeting of stockholders to be held on August 24, 2021 is a proposal to approve the amended and restated certificate of incorporation of the Company (the “Proposed Charter”), which would become effective following the closing of the Business Combination. The proxy statement/prospectus summarizes amendments that would be effected by the Proposed Charter, including changes to the Company’s authorized capital stock, the required vote to amend the Company’s certificate of incorporation in the future, the required vote to amend the Company’s bylaws in the future, the requirements that must be met to remove a member of the Board of Directors, the number of classes of the Board of Directors, the forum for the resolution of complaints asserting a cause of action arising under the Securities Act of 1933, as amended, and the removal of blank check company provisions. Please note that a vote in favor of this proposal would be a vote for the Proposed Charter in its entirety, including all of the above-described changes. If you vote in favor of the approval of the Proposed Charter but would like to express your views on some or all of the amendments to the current certificate of incorporation as advisory feedback to the Company’s Board of Directors, please send a letter to the attention of the Board of Directors of Locust Walk Acquisition Corp., c/o the Chief Executive Officer of Locust Walk Acquisition Corp., 200 Clarendon Street, 51st Floor, Boston, MA 02116.

    Additional Information and Where to Find It

    On May 26, 2021, eFFECTOR entered into a definitive Agreement and Plan of Merger (the “Merger Agreement”) with LWAC, a special purpose acquisition company, and Locust Walk Merger Sub, Inc., a wholly owned subsidiary of LWAC.

    In connection with the Merger Agreement, LWAC has filed a registration statement on Form S-4 with the SEC, which includes the proxy statement/prospectus. The proxy statement/prospectus was sent to all LWAC stockholders on or about August 13, 2021. LWAC will also file other documents regarding the Merger Agreement and the transactions contemplated thereby (the “Transactions”) with the SEC. Before making any voting decision, investors and security holders of LWAC are urged to read the registration statement, the proxy statement/prospectus and all other relevant documents filed with the SEC in connection with the Transactions as they become available because they will contain important information about the Transactions, including the terms of the Transactions, the parties involved and the risks associated with the Transactions.

    Investors and security holders will be able to obtain free copies of the registration statement, the proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC by LWAC through the website maintained by the SEC at www.sec.gov. Alternatively, these documents, when available, can be obtained free of charge from LWAC upon written request to Locust Walk Acquisition Corp., c/o eFFECTOR, 11120 Roselle Street, Suite A, San Diego, CA 92121, Attn: Secretary, or by calling (858) 925-8215.

    Participants in the Solicitation

    LWAC and eFFECTOR and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from LWAC’s stockholders in connection with the Transactions. A list of the names of the directors and executive officers of LWAC and information regarding their interests in the Transactions are contained in the proxy statement/prospectus. You may obtain free copies of these documents as described in the preceding paragraph.

    No Offer or Solicitation

    This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such other jurisdiction.


    Forward-Looking Statements

    This Current Report on Form 8-K contains certain forward-looking statements within the meaning of the federal securities laws with respect to the proposed transaction between LWAC and eFFECTOR All statements other than statements of historical facts contained in this report are forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to, the risk that the Transactions may not be completed in a timely manner or at all and the failure to satisfy the conditions to closing the Transactions. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond LWAC’s and eFFECTOR’s control, you should not rely on these forward-looking statements as predictions of future events. The foregoing list of factors is not exclusive, and you should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of LWAC’s Annual Report on Form 10-K for the year ended December 31, 2020 filed with SEC on March 29, 2021, the registration statement on Form S-4 discussed above and other documents filed by LWAC from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements, including the risk that the conditions under the Merger Agreement are not satisfied. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law. LWAC and eFFECTOR assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Neither LWAC nor eFFECTOR gives any assurance that either LWAC or eFFECTOR or the combined company will achieve its expectations.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Dated: August 23, 2021
    LOCUST WALK ACQUISITION CORP.
    By:  

    /s/ Chris Ehrlich

    Name:   Chris Ehrlich
    Title:   Chief Executive Officer
    Get the next $LWAC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LWAC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LWAC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Lightwave Founders Llc bought $6,062,500 worth of Class A ordinary shares (606,250 units at $10.00) (SEC Form 4)

    4 - LightWave Acquisition Corp. (0002061379) (Issuer)

    7/9/25 4:50:58 PM ET
    $LWAC

    $LWAC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Dickason Allen Charles

    3 - LightWave Acquisition Corp. (0002061379) (Issuer)

    7/9/25 4:54:59 PM ET
    $LWAC

    Large owner Lightwave Founders Llc bought $6,062,500 worth of Class A ordinary shares (606,250 units at $10.00) (SEC Form 4)

    4 - LightWave Acquisition Corp. (0002061379) (Issuer)

    7/9/25 4:50:58 PM ET
    $LWAC

    SEC Form 3 filed by new insider Lightwave Founders Llc

    3 - LightWave Acquisition Corp. (0002061379) (Issuer)

    6/24/25 9:27:54 PM ET
    $LWAC

    $LWAC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    LightWave Acquisition Corp. Announces Closing of $215,625,000 Initial Public Offering, Including Full Exercise of Underwriters' Over-Allotment Option

    Dallas, TX, June 26, 2025 (GLOBE NEWSWIRE) -- LightWave Acquisition Corp. (the "Company"), a newly organized special purpose acquisition company formed as a Cayman Islands exempted company, today announced the closing of its initial public offering of 21,562,500 units at an offering price of $10.00 per unit. This includes the exercise in full by the underwriters of their over-allotment option to purchase up to an additional 2,812,500 units. Each unit consists of one Class A ordinary share and one-half of one redeemable warrant. Each whole warrant will entitle the holder thereof to purchase one Class A ordinary share at $11.50 per share. The units are listed on the Nasdaq Global Market ("N

    6/26/25 3:07:28 PM ET
    $LWAC

    LightWave Acquisition Corp. Announces Pricing of $187,500,000 Initial Public Offering

    Dallas, TX, June 24, 2025 (GLOBE NEWSWIRE) -- LightWave Acquisition Corp. (the "Company"), a newly organized special purpose acquisition company formed as a Cayman Islands exempted company, today announced the pricing of its initial public offering of 18,750,000 units at an offering price of $10.00 per unit, with each unit consisting of one Class A ordinary share and one-half of one redeemable warrant. Each whole warrant, which becomes exercisable 30 days after the completion of the Company's initial business combination, will entitle the holder thereof to purchase one Class A ordinary share at $11.50 per share. The units are expected to trade on the Nasdaq Stock Market LLC ("Nasdaq") und

    6/24/25 6:44:57 PM ET
    $LWAC

    Locust Walk Acquisition Corp.'s Stockholders Approve Business Combination with eFFECTOR Therapeutics to Create Next-Generation Oncology Company Developing New Class of Cancer Therapies

    SAN DIEGO, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Locust Walk Acquisition Corp. (NASDAQ:LWAC) ("LWAC" or the "Company"), a special purpose acquisition company, announced today that the Company's stockholders have approved all proposals related to the previously announced business combination (the "Business Combination") with eFFECTOR Therapeutics, Inc. ("eFFECTOR") at a special meeting of stockholders held on August 24, 2021. Approximately 93.2% of the votes cast at the meeting on the Business Combination proposal, representing approximately 71.7% of LWAC's outstanding shares, voted to approve the Business Combination. LWAC stockholders also voted overwhelmingly to approve the other proposals

    8/24/21 4:47:39 PM ET
    $LWAC

    $LWAC
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by LightWave Acquisition Corp.

    SCHEDULE 13G/A - LightWave Acquisition Corp. (0002061379) (Subject)

    2/11/26 10:10:24 AM ET
    $LWAC

    SEC Form 10-Q filed by LightWave Acquisition Corp.

    10-Q - LightWave Acquisition Corp. (0002061379) (Filer)

    11/14/25 2:57:11 PM ET
    $LWAC

    Amendment: SEC Form SCHEDULE 13G/A filed by LightWave Acquisition Corp.

    SCHEDULE 13G/A - LightWave Acquisition Corp. (0002061379) (Subject)

    11/13/25 8:08:20 AM ET
    $LWAC

    $LWAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Locust Walk Acquisition Corp.

    SC 13D - eFFECTOR Therapeutics, Inc. (0001828522) (Subject)

    9/13/21 6:23:36 AM ET
    $LWAC

    SEC Form SC 13D filed by Locust Walk Acquisition Corp.

    SC 13D - eFFECTOR Therapeutics, Inc. (0001828522) (Subject)

    9/7/21 5:12:00 PM ET
    $LWAC

    SEC Form SC 13D filed by Locust Walk Acquisition Corp.

    SC 13D - eFFECTOR Therapeutics, Inc. (0001828522) (Subject)

    9/3/21 4:00:25 PM ET
    $LWAC